Ratings SMAIO

Equities

ALSMA

FR0014005I80

Real-time Euronext Paris Other stock markets 03:00:23 2024-06-11 am EDT			5-day change	1st Jan Change
3.77 ^EUR	-0.26%		+0.27%	+22.40%

Jan. 23	S.M.A.I.O S.A. Announces Unaudited Group Sales Results for the Year Ended December 31, 2023	CI
2023	S.M.A.I.O S.A. Reports Earnings Results for the Half Year Ended June 30, 2023	CI

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
The company is in a robust financial situation considering its net cash and margin position.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Over the past four months, analysts' average price target has been revised upwards significantly.

Weaknesses

The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
With an enterprise value anticipated at 2.99 times the sales for the current fiscal year, the company turns out to be overvalued.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
SMAIO	+22.40%	21.23M	-
ELI LILLY AND COMPANY	+48.39%	779B	C+
JOHNSON & JOHNSON	-6.13%	354B	C+
MERCK & CO., INC.	+20.61%	333B	B-
ABBVIE INC.	+10.00%	301B	C+
ASTRAZENECA PLC	+19.45%	249B	B+
ROCHE HOLDING AG	-1.60%	216B	A+
NOVARTIS AG	+11.74%	214B	B-
AMGEN INC.	+5.80%	163B	C+
PFIZER, INC.	-2.50%	159B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes